Zapnometinib is primarily investigated for its potential in treating inflammatory diseases and viral infections. It functions as a MEK inhibitor, targeting the MAPK/ERK pathway, which plays a critical role in cell proliferation and inflammation. In clinical studies, it has shown promise in reducing inflammation in conditions like rheumatoid arthritis and other autoimmune disorders. Additionally, it is being explored as a treatment for respiratory viral infections, including influenza and COVID-19, due to its ability to modulate immune responses and inhibit viral replication. Its application in oncology is also under research, particularly in cancers driven by mutations in the MAPK pathway. Its dual role in inflammation and viral replication makes it a versatile candidate for therapeutic development.